This website isn’t supported by Internet Explorer. We recommend that you use a different browser (e.g. Edge, Chrome, Firefox, Safari, or similar) for the best experience of our content.
Science Hub

Welcome to Novo Nordisk Science Hub

The information on this website is intended for healthcare professionals only and is provided solely for the purpose of scientific exchange. By accessing this website you accept this legal disclaimer and you expressly confirm your status as a healthcare professional.


This website is not country specific and may therefore contain information that is not applicable to your country. The website is not intended to provide medical advice and/or treatment guidance. Therefore, before prescribing any product, always refer to information approved by regulatory authorities in your country such as the prescribing information and/or the Summary of Product Characteristics. Novo Nordisk accepts no liability for the accuracy, completeness or use of information on this website, and disclaims any liability to update the information contained on this website.

Are you a healthcare professional?

Speaker - Cyrielle Caussy
Lyon 1 University, Lyon, France

Cyrielle Caussy is a Professor of Nutrition and an Endocrinologist-Diabetologist at Lyon 1 University and Lyon South Hospital in France. She is also the Medical Director adjunct of the Rhône-Alpes Research Center for Human Nutrition (CRNH Rhône-Alpes) with strong expertise in conducting clinical research in the Nutrition. During her medical training, she graduated with her PhD at Lyon 1 University studying the epigenetic regulation of lipid regulation at the CarMen laboratory (Cardio-Metabolism, Diabetes and Nutrition). Prof. Caussy’s main field of research interests are insulin resistance, obesity and non-alcoholic fatty liver disease (NAFLD). She completed a 2-year advanced research training at the NAFLD Research Center, University of California at San Diego directed by Dr Rohit Loomba. She now has a specific interest in non-invasive biomarkers and pathophysiology of NAFLD, especially in high-risk populations such as patients with type 2 diabetes and obesity. She is also co-leading a clinical and research program focused on metabolic liver disease at the Lyon Hepatology Institute.